<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Heart failure adults v2.0 MeG-CLS-040</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="heart-failure-in-adults">Heart failure in adults</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>Heart failure is a syndrome resulting from poor cardiac function. In the Gambia, the most common cause of this in adults is dilated cardiomyopathy secondary to long-standing untreated hypertension. Other causes include rheumatic heart disease, post-partum cardiomyopathy and, less commonly, ischaemic heart disease. Cardiac dysfunction might also be a consequence of chronic respiratory disease.</p>
<p>Heart failure may present acutely or more chronically. There may be signs of both poor perfusion of end organs and fluid overload. Left heart failure presents primarily with breathlessness. Right heart failure presents primarily with peripheral oedema. Congestive cardiac failure is the combination of both types. Acute left heart failure is a medical emergency and the patient should be sent to the ward (or to see the doctor in Keneba) as soon as possible.</p>
<p>Chronic left heart failure may be associated with preserved ejection fraction (HFpEF). This is managed differently from classical heart failure (HFrEF).</p>
<p>It is important to consider and treat both the underlying cause and possible exacerbating factors.</p>
<h2 id="target-users">Target users</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h2>
<p>This guideline outlines pragmatic management of acute and chronic heart failure in our setting.</p>
<h2 id="limitations">Limitations</h2>
<p>We lack access to HDU level care and cannot give inotropes.</p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Shortness of breath on exertion, at rest, or during the night.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Swelling of ankles / body.</p>
</div></li>
</ul>
<p>Grade the severity of symptoms using the New York Heart Association (NYHA) classification:</p>
<table>
<thead>
<tr class="header">
<th><strong>NYHA class</strong></th>
<th><strong>Symptoms</strong></th>
<th><strong>One-year mortality</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>I</td>
<td>No limitations</td>
<td>5-10%</td>
</tr>
<tr class="even">
<td>II</td>
<td>Slight limitation of activity – comfortable at rest and on mild exertion</td>
<td>15%</td>
</tr>
<tr class="odd">
<td>III</td>
<td>Marked limitation of activity – only comfortable at rest</td>
<td>30%</td>
</tr>
<tr class="even">
<td>IV</td>
<td>Any activity brings on discomfort – symptoms present at rest</td>
<td>50-60%</td>
</tr>
</tbody>
</table>
<h2 id="examination-findings">Examination findings</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Fast HR, Fast RR, Displaced apex beat, gallop rhythm, basal lung crackles, pleural effusions – all consistent with left heart failure.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Wheeze may be present (“cardiac asthma”) and does not usually respond to bronchodilator therapy.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Oedema, raised JVP, hepatomegaly – all consistent with right heart failure.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hypotension, confusion, cold peripheries are all suggestive of severe hypoperfusion.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hypertension – if this is the underlying cause.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Murmurs suggest underlying rheumatic or congenital heart disease.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Arrhythmia – might be cause of an acute exacerbation. In particular, look for atrial fibrillation (AF) and note that an automated BP cuff or oxygen saturation probe will not pick up an irregular pulse and may underestimate the apical pulse in AF.</p>
</div></li>
</ul>
<h3 id="important-things-to-look-for">Important things to look for</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Recent acute viral illness, TB, known HIV, known COPD, recent pregnancy, alcohol ingestion, smoking history – can all help to identify a possible cause.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Check adherence to medications.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Rule out intercurrent illness as cause of exacerbation.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Review medication history – for instance NSAIDs, aspirin and calcium channel blockers may worsen heart failure.</p>
</div></li>
</ul>
<h2 id="investigations">Investigations</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>FBC – as anaemia and infection may exacerbate heart failure.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>U&amp;Es – renal failure and electrolyte imbalances can complicate heart failure or its treatment.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>HIV – if there is no obvious cause or if there is any other suggestive features.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>CXR – for evidence of cardiomegaly, left heart failure or pericardial effusion.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>ECG – if there is arrhythmia, electrolyte imbalance or any reason to consider ischaemic heart disease.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>ECHO – to confirm diagnosis and identify cause. It is usually not necessary to do this at initial diagnosis, unless there is a reason to suspect valvular heart disease or pericardial disease. It is usually only necessary to confirm the cause of the heart failure and then does not need to be repeated unless there is a specific reason (passage of time from previous ECHO is not a good reason). Note that the ejection fraction may be preserved (indicating a diagnosis of HFpEF).</p>
</div></li>
</ul>
<p>It is not usually necessary to do LFTs – they are likely to be abnormal if there is right heart failure, but do not need specific treatment or monitoring.</p>
<h2 id="heart-failure-with-preserved-ejection-fraction">Heart failure with preserved ejection fraction</h2>
<p>HFpEF can only be diagnosed after an ECHO is done. There is much less study data available to direct treatment of this condition and thinking around it is changing rapidly. Worldwide, about half of patients presenting with signs of heart failure are found to have an ejection fraction of greater than 50%. This is associated with older age, hypertension, AF, diabetes mellitus, obesity, COPD, CKD and anaemia.</p>
<p>The diagnosis is made when patients present with clinical symptoms and signs of heart failure (dyspnoea, fatigue, raised JVP, crackles, peripheral oedema), but have a normal ECHO. These patients may also present with exertional chest pain, with normal coronary arteries. A CXR and ECG are useful, but they may be normal. An ECHO is essential.</p>
<p>Once an ECHO is done, HFpEF is diagnosed if the ejection fraction is normal (&gt;50%) and the LV volume is normal. Raised pulmonary pressure (ePASP &gt; 35 mmHg) and evidence of diastolic dysfunction are also expected.</p>
<p>The probability of HFpEF can be estimated by using the H2FPEF score outlined in the table on the next page. Each extra point in the score doubles the risk of HFpEF and higher scores are associated with poorer outcome.</p>
<table>
<thead>
<tr class="header">
<th></th>
<th><strong>Definition</strong></th>
<th><strong>Score</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>H</strong>eavy</td>
<td>BMI &gt; 30 kg/m<sup>2</sup></td>
<td>2</td>
</tr>
<tr class="even">
<td><strong>H</strong>ypertensive</td>
<td>Hypertensive and on 2 or more medicines</td>
<td>1</td>
</tr>
<tr class="odd">
<td>Atrial <strong>F</strong>ibrillation</td>
<td>Present</td>
<td>3</td>
</tr>
<tr class="even">
<td><strong>P</strong>ulmonary Hypertension</td>
<td>ePASP &gt; 35 mmHg</td>
<td>1</td>
</tr>
<tr class="odd">
<td><strong>E</strong>lder</td>
<td>Age &gt; 60 years</td>
<td>1</td>
</tr>
<tr class="even">
<td><strong>F</strong>illing pressure</td>
<td>ECHO E/e’ &gt; 9</td>
<td>1</td>
</tr>
</tbody>
</table>
<h2 id="management">Management</h2>
<p>The underlying problem should be treated once identified – however, in many cases, initial treatment will be determined by the presentation. A low salt diet will optimize diuresis and should be considered for all cases of heart failure.</p>
<h3 id="acute-left-heart-failure">Acute left heart failure</h3>
<p><em>This is an emergency – transfer the patient to the ward as soon as possible!</em></p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Sit the patient up. Give high flow O<sub>2</sub> to target saturations of 94-98% in those with low risk for Type II respiratory failure.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Give iv furosemide 40-80 mg.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Give morphine 5-10 mg iv only if the patient is in severe respiratory distress.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Consider treating any underlying arrhythmia.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Reassess the patient – furosemide can be repeated to a maximum of 160 mg</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Sublingual nitrates or iv nitrates may be helpful if available and blood pressure permits. Intravenous nitrates should be administered under close monitoring (ideally HDU level care). Note that iv nitrates should be stopped after 24 hours as tolerance develops and they lose efficacy.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Beta blockers, if already being taken, should be continued unless heart rate &lt;50; 2<sup>nd</sup> or 3<sup>rd</sup> degree AV block or shock (in which case they should be stopped)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Non-invasive ventilation, if available, should be considered in patients with cardiogenic pulmonary oedema, severe dyspnea and acidaemia.</p>
</div></li>
</ul>
<p>If a patient fails to respond to iv furosemide, consider the use of a continuous furosemide infusion. There are theoretical reasons why this might be more effective and some study evidence to support its use. Give the same total dose of furosemide over 24 hours via syringe driver up to a maximum dose of 720 mg per day.</p>
<p>If there are is still no improvement and you have no other options, you can consider venesection, if the patient is shocked, but not anaemic, or the use of a loading dose of iv aminophylline (5 mg/kg over 20 minutes via syringe driver) – it has diuretic, positive chronotropic and inotropic actions. The second of these is not supported by guidelines, but may buy some time if you are desperate.</p>
<p>Add other treatments as tolerated during admission and whilst keeping a close eye on the renal function. Serum sodium, potassium and creatinine should be monitored regularly on all patients that are having a significant diuresis.</p>
<h3 id="left-heart-failure">Left heart failure</h3>
<p>Use this guidance for a newly diagnosed patient who is not acutely ill or once a patient with acute left heart failure is stabilized. Treatment should be stepped up gradually in the order listed below as the patient’s blood pressure and renal function allow. Check BP at every appointment. Check renal function at least once after any major change in treatment or if there is a change in the patient’s condition.</p>
<p>Begin treatment with oral <strong>furosemide</strong> 40-160 mg per day to reduce oedema and congestion of the lungs. Furosemide doses greater than 80 mg daily should be given as a split (twice daily dose). Ideally furosemide should not be given later than 2pm to avoid sleep disturbance from nocturia.</p>
<p>Add an <strong>ACE inhibitor</strong> next. This improves prognosis. Do not use if there is hypotension, hyperkalaemia, renal artery stenosis or stenotic cardiac valvular disease. Enalapril is our first line option. Use 2.5 mg OD and increase to maximum dose of 20 mg BD as tolerated. Captopril is available if the patient will be transferred back to government care in the near future. Ramipril may also be available.</p>
<p><strong>Beta-blockers</strong> should be used only in stable patients. Again they improve prognosis. First line choice for control of HR in atrial fibrillation. Avoid in asthma. Do not give if HR is below 50 bpm or there is 2<sup>nd</sup> or 3<sup>rd</sup> degree heart block. If the patient presented with acute heart failure, do not start until they return for follow-up or until they have been managed or oral diuretics for 1-2 days. Give bisoprolol 1.25 mg – 2.5 mg OD and increase as tolerated (start titration after 2 weeks) to a maximum dose of 10 mg OD.</p>
<p><strong>Spironolactone</strong> improves prognosis in patients with moderate or severe heart failure who are already on an ACE inhibitor. It can cause severe hyperkalaemia. Give 25-50 mg OD.</p>
<p><strong>Digoxin</strong> may improve symptoms and reduce hospital admission. No evidence of improved prognosis. High risk of toxicity, especially in elderly patients or those with renal failure. Toxicity presents with bradycardia, nausea and vomiting, altered vision. Give 2 doses of 0.5 mg 12 hours apart then continue maintenance treatment with 0.12-0.25 mg OD.</p>
<p><strong>Isosorbide dinitrate</strong> and <strong>hydralazine</strong> in combination with the above treatments have been shown to help black patients who have NYHA class III-IV heart failure and reduced ejection fraction unresponsive to standard treatment. Contraindicated in mitral or aortic stenosis, pericardial effusion and constrictive pericarditis. Give 20-80 mg isosorbide dinitrate TDS (to maximum dose of 240 mg daily) and hydralazine 25-100 mg QDS. These drugs are not on our formulary and must be purchased by patients in private pharmacies.</p>
<p>If the patient is hypertensive and standard heart failure treatment has not brought the blood pressure down, amlodipine can be added to achieve this.</p>
<p>Where there is evidence of ischaemic heart disease, aspirin, clopidogrel and statins should be considered.</p>
<h3 id="target-doses-for-drugs-in-left-heart-failure">Target doses for drugs in left heart failure:</h3>
<p>These targets will usually be met by increasing the doses of drugs slowly in the OPD (eg every 2-4 weeks). Assess all the drugs being prescribed and consider stopping other medications as well as the HF meds if significant side effects are observed.</p>
<table>
<thead>
<tr class="header">
<th><strong>Drug class</strong></th>
<th><strong>Side effects</strong></th>
<th><strong>Target doses</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>ACE Inhibitors</td>
<td><p>Rise in K+ &gt;5.5 mmol/L</p>
<p>Rise in creatinine &gt; 266mmol/L or 50% of baseline</p>
<p>Symptomatic hypotension (including postural symptoms)</p>
<p>Severe cough, not related to HF or other pathology and may be tolerable if patients understand it is related to drugs</p></td>
<td><p>Enalapril 10-20 mg BD</p>
<p>Ramipril 5 mg BD</p>
<p>Captopril 50 mg TDS</p>
<p>Lisinopril 20 mg OD</p></td>
</tr>
<tr class="even">
<td>Beta blockers</td>
<td><p>Symptomatic hypotension (including postural symptoms)</p>
<p>Bradycardia (&lt;50 bpm)</p>
<p>Worsening heart failure symptoms</p>
<p>Fatigue</p></td>
<td>Bisoprolol 10 mg OD</td>
</tr>
</tbody>
</table>
<h3 id="heart-failure-with-preserved-ejection-fraction-1">Heart failure with preserved ejection fraction</h3>
<p>Management of HFpEF is mainly directed against symptoms and associated conditions as no studies have shown any improvement in long term outcomes for other treatments.</p>
<p>Hypertension should be adequately controlled and diuretics should be used to relieve symptoms associated with fluid overload. In controlling blood pressure, thiazides are believed to have some association with better outcomes than amlodipine or ACE inhibitors, so should be prioritized if possible.</p>
<p>If AF is present, rate control is helpful.</p>
<p>If ischaemia is present, treatment with beta blockers is indicated.</p>
<p>If there is raised cholesterol, statins may improve outcomes (observations studies only).</p>
<p>Spironolactone has been studied in this condition and is recommended alongside furosemide. It was associated with reduced hospitalisations, but not reduced mortality. Dosing was limited by raised K and renal function.</p>
<p>In short, furosemide and spironolactone are indicated to treat oedema and shortness of breath. Other treatments are not helpful unless there is some other indication for them.</p>
<h3 id="right-heart-failure">Right heart failure</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Exclude pericardial effusion by echocardiography.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Treat primary pulmonary condition (for instance giving salbutamol inhaler or nebulisers to patients with COPD).</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Add furosemide and spironolactone to treat oedema. ACE inhibitors and other treatment for left heart failure are not indicated.</p>
</div></li>
</ul>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Heart failure should not be managed in Gate clinic, but must be referred to the doctors in OPD.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Patients admitted with severe heart failure should be nursed in an upright position, with their legs slightly raised above their hips.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Any dose of furosemide above 60 mg iv should be given over at least 20 minutes using a syringe driver.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Patients on iv diuretics should have close monitoring of weight (daily) and urine output (in/out chart).</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p>National Institute for Health and Care Excellence (2014). Acute heart failure: diagnosis and management. NICE guideline (CG187).</p>
<p>National Institute for Health and Care Excellence (2018). Chronic heart failure: diagnosis and management. NICE guideline (NG106).</p>
<p>Health Improvement Scotland SIGN 147 (2016) Management of Chronic Heart Failure</p>
<p>Sloan, Phiri and Zijlstra (2012). The clinical book of the Department of Medicine, College of Medicine, Blantyre, Malawi.</p>
<p>Ellison and Felker (2017). Diuretic treatment in heart failure. N Engl J Med 2017; 377:1964-75.</p>
<p>Borlaug (2020). Heart failure with preserved ejection fraction: clinical manifestations and diagnosis. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA.</p>
<p>Borlaug and Colucci (2020). Treatment and prognosis of eart failure with preserved ejection fraction. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA.</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Karen Forrest</th>
<th>Date: 22 May 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Fatai Akemokwe</td>
<td>Date: 17 June 2018</td>
</tr>
<tr class="even">
<td><strong>Reviewed by:</strong></td>
<td>Name: Behzad Nadjm</td>
<td>Date: <em>18</em> November 2020</td>
</tr>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Karen Forrest</td>
<td>Date: <em>18</em> December 2020</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>15 August 2020</td>
</tr>
<tr class="even">
<td>1.1</td>
<td>Executive summary added</td>
<td>15 August 2020</td>
</tr>
<tr class="odd">
<td>2.0</td>
<td>Changes to first line ACEi, updated information about best practice of combination treatment for chronic left heart failure, addition of section on HFpEF</td>
<td><em>18</em> December 2022</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
